The Experts below are selected from a list of 20013 Experts worldwide ranked by ideXlab platform
Cynthia Rodenberg - One of the best experts on this subject based on the ideXlab platform.
-
Clinically relevant changes in sexual desire, satisfying sexual activity and Personal Distress as measured by the profile of female sexual function, sexual activity log, and Personal Distress scale in postmenopausal women with hypoactive sexual desir
The journal of sexual medicine, 2009Co-Authors: Leonard R. Derogatis, Alessandra Graziottin, Johannes Bitzer, Sonja Schmitt, Patricia E. Koochaki, Cynthia RodenbergAbstract:ABSTRACT Introduction Transdermal testosterone patch (TTP) treatment produced statistically significant improvements in a satisfying sexual activity (SSA), sexual desire, and Personal Distress in postmenopausal women suffering from hypoactive sexual desire disorder (HSDD), but clinical significance of these changes was not determined. Aim To quantify the magnitude of change in three principal outcomes measures determined by HSDD patients as associated with the perception of meaningful benefit with TTP therapy. Methods The criteria for defining responders were determined using anchoring methodology and receiver operating characteristics analysis to establish minimum important differences (MIDs) in a representative subsample of 132 patients in two randomized, controlled trials in surgically menopausal women with HSDD (N = 1,094). Perceived benefit was established based upon the question “Overall, would you say that you experienced a meaningful benefit from the study patches?”. These data defined responders and established MIDs for changes in sexual desire, SSA, and Personal Distress. The MIDs were applied to the two trials to establish responder rates in each treatment group. Main Outcome Measures Changes in score that correspond to the MID for sexual desire, SSA, and Personal Distress, and responder rates in each treatment group based upon these values. Results Increases in frequency of SSA of greater than 1 activity/4 weeks, increases in sexual desire score of ≥8.9, and decreases in the Personal Distress score of ≥20.0 were identified as threshold improvements best able to differentiate responders and nonresponders. The responder rate was significantly higher ( P Conclusions Changes in sexual desire, SSA, and Personal Distress observed with TTP treatment in surgically menopausal women with HSDD were clinically significant and were associated with a meaningful treatment benefit. DeRogatis LR, Graziottin A, Bitzer J, Schmitt S, Koochaki PE, and Rodenberg C. Clinically relevant changes in sexual desire, satisfying sexual activity and Personal Distress as measured by the profile of female sexual function, sexual activity log, and Personal Distress scale in postmenopausal women with hypoactive sexual desire disorder. J Sex Med 2009;6:175–183.
-
clinically relevant changes in sexual desire satisfying sexual activity and Personal Distress as measured by the profile of female sexual function sexual activity log and Personal Distress scale in postmenopausal women with hypoactive sexual desire d
The Journal of Sexual Medicine, 2009Co-Authors: Leonard R. Derogatis, Alessandra Graziottin, Johannes Bitzer, Sonja Schmitt, Patricia E. Koochaki, Cynthia RodenbergAbstract:Introduction Transdermal testosterone patch (TTP) treatment produced statistically significant improvements in a satisfying sexual activity (SSA), sexual desire, and Personal Distress in postmenopausal women suffering from hypoactive sexual desire disorder (HSDD), but clinical significance of these changes was not determined.
Leonard R. Derogatis - One of the best experts on this subject based on the ideXlab platform.
-
Clinically relevant changes in sexual desire, satisfying sexual activity and Personal Distress as measured by the profile of female sexual function, sexual activity log, and Personal Distress scale in postmenopausal women with hypoactive sexual desir
The journal of sexual medicine, 2009Co-Authors: Leonard R. Derogatis, Alessandra Graziottin, Johannes Bitzer, Sonja Schmitt, Patricia E. Koochaki, Cynthia RodenbergAbstract:ABSTRACT Introduction Transdermal testosterone patch (TTP) treatment produced statistically significant improvements in a satisfying sexual activity (SSA), sexual desire, and Personal Distress in postmenopausal women suffering from hypoactive sexual desire disorder (HSDD), but clinical significance of these changes was not determined. Aim To quantify the magnitude of change in three principal outcomes measures determined by HSDD patients as associated with the perception of meaningful benefit with TTP therapy. Methods The criteria for defining responders were determined using anchoring methodology and receiver operating characteristics analysis to establish minimum important differences (MIDs) in a representative subsample of 132 patients in two randomized, controlled trials in surgically menopausal women with HSDD (N = 1,094). Perceived benefit was established based upon the question “Overall, would you say that you experienced a meaningful benefit from the study patches?”. These data defined responders and established MIDs for changes in sexual desire, SSA, and Personal Distress. The MIDs were applied to the two trials to establish responder rates in each treatment group. Main Outcome Measures Changes in score that correspond to the MID for sexual desire, SSA, and Personal Distress, and responder rates in each treatment group based upon these values. Results Increases in frequency of SSA of greater than 1 activity/4 weeks, increases in sexual desire score of ≥8.9, and decreases in the Personal Distress score of ≥20.0 were identified as threshold improvements best able to differentiate responders and nonresponders. The responder rate was significantly higher ( P Conclusions Changes in sexual desire, SSA, and Personal Distress observed with TTP treatment in surgically menopausal women with HSDD were clinically significant and were associated with a meaningful treatment benefit. DeRogatis LR, Graziottin A, Bitzer J, Schmitt S, Koochaki PE, and Rodenberg C. Clinically relevant changes in sexual desire, satisfying sexual activity and Personal Distress as measured by the profile of female sexual function, sexual activity log, and Personal Distress scale in postmenopausal women with hypoactive sexual desire disorder. J Sex Med 2009;6:175–183.
-
clinically relevant changes in sexual desire satisfying sexual activity and Personal Distress as measured by the profile of female sexual function sexual activity log and Personal Distress scale in postmenopausal women with hypoactive sexual desire d
The Journal of Sexual Medicine, 2009Co-Authors: Leonard R. Derogatis, Alessandra Graziottin, Johannes Bitzer, Sonja Schmitt, Patricia E. Koochaki, Cynthia RodenbergAbstract:Introduction Transdermal testosterone patch (TTP) treatment produced statistically significant improvements in a satisfying sexual activity (SSA), sexual desire, and Personal Distress in postmenopausal women suffering from hypoactive sexual desire disorder (HSDD), but clinical significance of these changes was not determined.
-
the female sexual Distress scale fsds initial validation of a standardized scale for assessment of sexually related Personal Distress in women
Journal of Sex & Marital Therapy, 2002Co-Authors: Leonard R. Derogatis, Raymond C. Rosen, Sandra R. Leiblum, Arthur L. Burnett, Julia R. HeimanAbstract:Recent consensus-based characterizations of female sexual dysfunction have emphasized Personal Distress as an essential component of their definition. To assist researchers and clinicians, we developed a new scale, the Female Sexual Distress Scale, to measure sexually related Personal Distress in women. In this article, we describe the initial stages in the development and validation of this instrument. Three studies involving a total of approximately 500 women were performed to evaluate the reliability and validity of the scale in different samples of sexually functional and dysfunctional women. Results indicated a unidimensional factor structure in both the original 20-item version and in a "polished" 12-item version. We observed a high degree of internal consistency and test-retest reliability in both versions across all three studies. Additionally, the scale showed a high degree of discriminative ability to distinguish between sexually dysfunctional and functional women in each of the studies. One stu...
-
The Female Sexual Distress Scale (FSDS): initial validation of a standardized scale for assessment of sexually related Personal Distress in women.
Journal of sex & marital therapy, 2002Co-Authors: Leonard R. Derogatis, Raymond C. Rosen, Sandra R. Leiblum, Arthur L. Burnett, Julia R. HeimanAbstract:Recent consensus-based characterizations of female sexual dysfunction have emphasized Personal Distress as an essential component of their definition. To assist researchers and clinicians, we developed a new scale, the Female Sexual Distress Scale, to measure sexually related Personal Distress in women. In this article, we describe the initial stages in the development and validation of this instrument. Three studies involving a total of approximately 500 women were performed to evaluate the reliability and validity of the scale in different samples of sexually functional and dysfunctional women. Results indicated a unidimensional factor structure in both the original 20-item version and in a "polished" 12-item version. We observed a high degree of internal consistency and test-retest reliability in both versions across all three studies. Additionally, the scale showed a high degree of discriminative ability to distinguish between sexually dysfunctional and functional women in each of the studies. One study also showed a strong sensitivity to treatment response. Finally, we observed moderate positive correlations with other conceptually related nonsexual measures of Distress, supporting the construct validity of the scale. Overall, these findings provide solid support for the FSDS as a valid and reliable measure for assessing sexually related Personal Distress in women.
Susan R. Davis - One of the best experts on this subject based on the ideXlab platform.
-
The prevalence of sexual dysfunctions and sexually related Distress in young women: a cross-sectional survey.
Fertility and sterility, 2020Co-Authors: Jia Zheng, Robin J. Bell, Marina A. Skiba, Rakibul M. Islam, Susan R. DavisAbstract:Objective To document the prevalence of female sexual dysfunctions (FSDs) and factors associated with FSDs and sexually related Personal Distress in premenopausal women. Design Community-based cross-sectional study. Setting Eastern states of Australia. Participants Women aged 18–39 years. Interventions(s) Not applicable. Main Outcome Measure(s) Women were classified as having sexually related Personal Distress if they had a Female Sexual Distress Scale–Revised score of ≥11, and as having an FSD if they had a low Profile of Female Sexual Function desire, arousal, orgasmic function, responsiveness, or sexual self-image domain score plus sexually related Personal Distress. Sociodemographic factors associated with an FSD were examined by means of multivariable logistic regression. Result(s) The prevalence of sexually related Personal Distress was 50.2%. Sexually related Personal Distress without dysfunction affected 29.6%, and 20.6% had at least one FSD. The proportions of women with self-image, arousal, desire, orgasm, and responsiveness dysfunction were 11.1%, 9%, 8%, 7.9%, and 3.4% respectively. Sexual self-image dysfunction was associated with being overweight, obese, living together, not married, married, breastfeeding, and taking a psychotropic medication. Psychotropic medication was significantly associated with all FSDs. Independent risk factors for nonspecific sexually related Personal Distress included psychotropic medication., sexual inactivity, and infertility treatment. Conclusion(s) That one-half of young Australian women have sexually related Personal Distress and one in five women have at least an FSD, with sexual self-image predominating, is concerning. The high prevalence of Distress signals the importance of health professionals being adequately prepared to discuss sexual health concerns.
-
Prevalence and Predictors of Low Sexual Desire, Sexually Related Personal Distress, and Hypoactive Sexual Desire Dysfunction in a Community-Based Sample of Midlife Women
The journal of sexual medicine, 2017Co-Authors: Roisin Worsley, Robin J. Bell, Pragya Gartoulla, Susan R. DavisAbstract:Abstract Background Low desire is the most common sexual problem in women at midlife. Prevalence data are limited by lack of validated instruments or exclusion of un-partnered or sexually inactive women. Aim To document the prevalence of and factors associated with low desire, sexually related Personal Distress, and hypoactive sexual desire dysfunction (HSDD) using validated instruments. Methods Cross-sectional, nationally representative, community-based sample of 2,020 Australian women 40 to 65 years old. Outcomes Low desire was defined as a score no higher than 5.0 on the desire domain of the Female Sexual Function Index (FSFI); sexually related Personal Distress was defined as a score of at least 11.0 on the Female Sexual Distress Scale–Revised; and HSDD was defined as a combination of these scores. The Menopause Specific Quality of Life Questionnaire was used to document menopausal vasomotor symptoms. The Beck Depression Inventory–II was used to identify moderate to severe depressive symptoms (score ≥ 20). Results The prevalence of low desire was 69.3% (95% CI = 67.3–71.3), that of sexually related Personal Distress was 40.5% (95% CI = 38.4–42.6), and that of HSDD was 32.2% (95% CI = 30.1–34.2). Of women who were not partnered or sexually active, 32.4% (95% CI = 24.4–40.2) reported sexually related Personal Distress. Factors associated with HSDD in an adjusted logistic regression model included being partnered (odds ratio [OR] = 3.30, 95% CI = 2.46–4.41), consuming alcohol (OR = 1.48, 95% CI = 1.16–1.89), vaginal dryness (OR = 2.08, 95% CI = 1.66–2.61), pain during or after intercourse (OR = 1.63, 95% CI = 1.27–2.09), moderate to severe depressive symptoms (OR = 2.69, 95% CI 1.99–3.64), and use of psychotropic medication (OR = 1.42, 95% CI = 1.10–1.83). Vasomotor symptoms were not associated with low desire, sexually related Personal Distress, or HSDD. Clinical Implications Given the high prevalence, clinicians should screen midlife women for HSDD. Strengths and Limitations Strengths include the large size and representative nature of the sample and the use of validated tools. Limitations include the requirement to complete a written questionnaire in English. Questions within the FSFI limit the applicability of FSFI total scores, but not desire domain scores, in recently sexually inactive women, women without a partner, and women who do not engage in penetrative intercourse. Conclusions Low desire, sexually related Personal Distress, and HSDD are common in women at midlife, including women who are un-partnered or sexually inactive. Some factors associated with HSDD, such as psychotropic medication use and vaginal dryness, are modifiable or can be treated with safe and effective therapies. Worsley R, Bell RJ, Gartoulla P, Davis SR. Prevalence and Predictors of Low Sexual Desire, Sexually Related Personal Distress, and Hypoactive Sexual Desire Dysfunction in a Community-Based Sample of Midlife Women. J Sex Med 2017;14:675–686.
Patricia E. Koochaki - One of the best experts on this subject based on the ideXlab platform.
-
Clinically relevant changes in sexual desire, satisfying sexual activity and Personal Distress as measured by the profile of female sexual function, sexual activity log, and Personal Distress scale in postmenopausal women with hypoactive sexual desir
The journal of sexual medicine, 2009Co-Authors: Leonard R. Derogatis, Alessandra Graziottin, Johannes Bitzer, Sonja Schmitt, Patricia E. Koochaki, Cynthia RodenbergAbstract:ABSTRACT Introduction Transdermal testosterone patch (TTP) treatment produced statistically significant improvements in a satisfying sexual activity (SSA), sexual desire, and Personal Distress in postmenopausal women suffering from hypoactive sexual desire disorder (HSDD), but clinical significance of these changes was not determined. Aim To quantify the magnitude of change in three principal outcomes measures determined by HSDD patients as associated with the perception of meaningful benefit with TTP therapy. Methods The criteria for defining responders were determined using anchoring methodology and receiver operating characteristics analysis to establish minimum important differences (MIDs) in a representative subsample of 132 patients in two randomized, controlled trials in surgically menopausal women with HSDD (N = 1,094). Perceived benefit was established based upon the question “Overall, would you say that you experienced a meaningful benefit from the study patches?”. These data defined responders and established MIDs for changes in sexual desire, SSA, and Personal Distress. The MIDs were applied to the two trials to establish responder rates in each treatment group. Main Outcome Measures Changes in score that correspond to the MID for sexual desire, SSA, and Personal Distress, and responder rates in each treatment group based upon these values. Results Increases in frequency of SSA of greater than 1 activity/4 weeks, increases in sexual desire score of ≥8.9, and decreases in the Personal Distress score of ≥20.0 were identified as threshold improvements best able to differentiate responders and nonresponders. The responder rate was significantly higher ( P Conclusions Changes in sexual desire, SSA, and Personal Distress observed with TTP treatment in surgically menopausal women with HSDD were clinically significant and were associated with a meaningful treatment benefit. DeRogatis LR, Graziottin A, Bitzer J, Schmitt S, Koochaki PE, and Rodenberg C. Clinically relevant changes in sexual desire, satisfying sexual activity and Personal Distress as measured by the profile of female sexual function, sexual activity log, and Personal Distress scale in postmenopausal women with hypoactive sexual desire disorder. J Sex Med 2009;6:175–183.
-
clinically relevant changes in sexual desire satisfying sexual activity and Personal Distress as measured by the profile of female sexual function sexual activity log and Personal Distress scale in postmenopausal women with hypoactive sexual desire d
The Journal of Sexual Medicine, 2009Co-Authors: Leonard R. Derogatis, Alessandra Graziottin, Johannes Bitzer, Sonja Schmitt, Patricia E. Koochaki, Cynthia RodenbergAbstract:Introduction Transdermal testosterone patch (TTP) treatment produced statistically significant improvements in a satisfying sexual activity (SSA), sexual desire, and Personal Distress in postmenopausal women suffering from hypoactive sexual desire disorder (HSDD), but clinical significance of these changes was not determined.
Sonja Schmitt - One of the best experts on this subject based on the ideXlab platform.
-
Clinically relevant changes in sexual desire, satisfying sexual activity and Personal Distress as measured by the profile of female sexual function, sexual activity log, and Personal Distress scale in postmenopausal women with hypoactive sexual desir
The journal of sexual medicine, 2009Co-Authors: Leonard R. Derogatis, Alessandra Graziottin, Johannes Bitzer, Sonja Schmitt, Patricia E. Koochaki, Cynthia RodenbergAbstract:ABSTRACT Introduction Transdermal testosterone patch (TTP) treatment produced statistically significant improvements in a satisfying sexual activity (SSA), sexual desire, and Personal Distress in postmenopausal women suffering from hypoactive sexual desire disorder (HSDD), but clinical significance of these changes was not determined. Aim To quantify the magnitude of change in three principal outcomes measures determined by HSDD patients as associated with the perception of meaningful benefit with TTP therapy. Methods The criteria for defining responders were determined using anchoring methodology and receiver operating characteristics analysis to establish minimum important differences (MIDs) in a representative subsample of 132 patients in two randomized, controlled trials in surgically menopausal women with HSDD (N = 1,094). Perceived benefit was established based upon the question “Overall, would you say that you experienced a meaningful benefit from the study patches?”. These data defined responders and established MIDs for changes in sexual desire, SSA, and Personal Distress. The MIDs were applied to the two trials to establish responder rates in each treatment group. Main Outcome Measures Changes in score that correspond to the MID for sexual desire, SSA, and Personal Distress, and responder rates in each treatment group based upon these values. Results Increases in frequency of SSA of greater than 1 activity/4 weeks, increases in sexual desire score of ≥8.9, and decreases in the Personal Distress score of ≥20.0 were identified as threshold improvements best able to differentiate responders and nonresponders. The responder rate was significantly higher ( P Conclusions Changes in sexual desire, SSA, and Personal Distress observed with TTP treatment in surgically menopausal women with HSDD were clinically significant and were associated with a meaningful treatment benefit. DeRogatis LR, Graziottin A, Bitzer J, Schmitt S, Koochaki PE, and Rodenberg C. Clinically relevant changes in sexual desire, satisfying sexual activity and Personal Distress as measured by the profile of female sexual function, sexual activity log, and Personal Distress scale in postmenopausal women with hypoactive sexual desire disorder. J Sex Med 2009;6:175–183.
-
clinically relevant changes in sexual desire satisfying sexual activity and Personal Distress as measured by the profile of female sexual function sexual activity log and Personal Distress scale in postmenopausal women with hypoactive sexual desire d
The Journal of Sexual Medicine, 2009Co-Authors: Leonard R. Derogatis, Alessandra Graziottin, Johannes Bitzer, Sonja Schmitt, Patricia E. Koochaki, Cynthia RodenbergAbstract:Introduction Transdermal testosterone patch (TTP) treatment produced statistically significant improvements in a satisfying sexual activity (SSA), sexual desire, and Personal Distress in postmenopausal women suffering from hypoactive sexual desire disorder (HSDD), but clinical significance of these changes was not determined.